{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-426811","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2026-10-20T20:57:30+00:00","discovered_at":"2026-10-20T20:58:00.466007+00:00","generated_at":"2026-10-20T20:58:03.341421+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Inhibikase adds Amgen vet Scott Wasserman to board; Dennis Berman resigns","bullets":["Scott M. Wasserman, MD, appointed Class III director effective October 19, 2026, serving until the 2029 annual meeting; he joins the Compensation Committee.","Wasserman gets an initial grant of non-qualified options for up to 310,000 IKT shares plus cash compensation under the non-employee director policy.","Wasserman is CMO of Kailera Therapeutics; at Amgen he led global development and approvals of Repatha, Evenity and Aimovig.","Dennis Berman resigned the same day as director and Compensation Committee chair and Audit Committee member; no disagreement cited.","Chairman Amit Munshi cited Wasserman's expertise as Inhibikase advances the global Phase 3 IMPROVE-PAH study of oral IKT-001 for PAH."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-426811","json":"https://secwatch.observer/filing/0001193125-26-426811.json","markdown":"https://secwatch.observer/filing/0001193125-26-426811.md","text":"https://secwatch.observer/filing/0001193125-26-426811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526426811/0001193125-26-426811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526426811/d190975d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-20T20:58:03.341421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2dd2da7821","claim":"Scott Wasserman was appointed as Class III director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"On October 19, 2026, the Board, upon the recommendation of the Board’s Corporate Governance and Nominating Committee, appointed Scott Wasserman to serve as a Class III director, to hold office until the Company’s annual meeting of stockholders in 2029 or until his earlier death, resignation or removal, effective as of October 19, 2026 (the “Appointment Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526426811/0001193125-26-426811-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"},{"claim_id":"bb5c21b8d2","claim":"Dennis Berman resigned as Director; Chair of the Compensation Committee; member of the Audit Committee at Inhibikase Therapeutics, Inc..","evidence_excerpt":"On October 19, 2026, Dennis Berman resigned from the board of directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) and his position as Chair of the Compensation Committee of the Board (the “Compensation Committee”) and a member of the Audit Committee of the Board (the “Audit Committee”), effective as of October 19, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526426811/0001193125-26-426811-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director; Chair of the Compensation Committee; member of the Audit Committee"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}